| ID | Name | CAS |
MW (g/mol) |
| 61-490-0 |
2-Butyl-3-benzofuranyl 4-[(2-diethylamino)ethoxy] 3,5-diiodophenyl ketone, hydrochloride
|
19774-82-4 | 681.77 |
| 51-134-6 |
Bismuth oxalate
|
| 682.02 |
| 47-586-0 |
N6-TMS-Adenosine, 2',3',5'-tris-O-TBDMS
|
| 682.21 |
| 40-059-2 |
5-Androsten-3-«alpha»,17-«beta»-diol, HFB
|
| 682.49 |
| 14-232-8 |
5-«alpha»-Androst-9(11)-ene-3-«alpha»,17-«beta»-diol, HFB
|
| 682.49 |
| 11-713-7 |
5-Androsten-3-«beta»,17-«alpha»-diol, HFB
|
| 682.49 |
| 49-660-5 |
5-Androsten-3-«beta»,17-«beta»-diol, HFB
|
| 682.49 |
| 35-996-8 |
1,3,5(10)-Oestratriene-2-methoxy-3,16«alpha»,17«beta»-triol, 3-TMS-16,17-PFP
|
| 682.62 |
| 18-210-8 |
Acetic acid, [3-hydroxy-4,4'-carbonylbis(phenyleneoxy)di-], didodecyl ester
|
116436-40-9 | 682.93 |
| 119-019-9 |
Rhodoporphyrin-XV homologue, bis(trimethylsiloxy)silicon(IV) derivative
|
| 683.00 |
| 118-060-4 |
Deuteroporphyrin-IX dimethyl ester, bis(trimethylsiloxy)silicon(IV) derivative
|
| 683.00 |
| 58-551-6 |
GA75, MeTMSi
|
| 683.14 |
| 40-642-4 |
GA86, MeTMSi
|
| 683.14 |
| 45-519-6 |
GA89, MeTMSi
|
| 683.14 |
| 88-450-5 |
Triamcinolone tetra-TMS
|
| 683.16 |
| 77-761-2 |
1,3,5-Triselena-2,4,6-tristannacyclohexane, 2,2,4,4,6,6-hexamethyl-
|
58258-49-4 | 683.22 |
| 39-791-1 |
5B-Cholane-3A,7A,12A,24-tetrol, TMS
|
| 683.31 |
| 31-660-4 |
5«beta»-Cholane-3«alpha»,7«alpha»,12«alpha»,24-tetrol, TMS
|
| 683.31 |
| 12-588-6 |
Beta-diethylaminoethyl-9-xanthene-carboxylate di-cyclohexylsulfamate
|
| 683.88 |
| 81-545-7 |
«beta»-D-Glucopyranoside, 2,3,4,6-tetrakis-(O-trimethylsilyl)-1-(trimethylsilyl)-1H-indole-3-acetate
|
| 684.20 |
| 29-868-7 |
Cortolone MO TMS
|
| 684.26 |
| 48-340-1 |
A-Cortolone, MO TMS
|
| 684.26 |
| 60-948-3 |
3A,11B,17A,21-Tetrahydroxy-5B-pregnan-20-one, MO TMS
|
| 684.26 |
| 62-827-5 |
Tetrahydrocortisol, MO-tetra-TMS
|
| 684.26 |
| 49-447-2 |
B-Cortolone MO TMS
|
| 684.26 |
| 70-690-8 |
3A,11B,17A,21-Tetrahydroxy-5A-pregnan-20-one, MO TMS
|
| 684.26 |
| 53-457-6 |
5-«alpha»-Androstan-3-«beta»,16-«beta»-diol, HFB
|
| 684.50 |
| 43-833-9 |
5-«alpha»-Androstan-3-«alpha»,17-«alpha»-diol, HFB
|
| 684.50 |
| 40-264-4 |
5-«alpha»-Androstan-7-«alpha»,17-«beta»-diol, HFB
|
| 684.50 |
| 11-678-7 |
5-«alpha»-Androstan-3-«beta»,17-«beta»-diol, HFB
|
| 684.50 |
| 43-422-5 |
5-«beta»-Androstan-3-«alpha»,17-«alpha»-diol, HFB
|
| 684.50 |
| 24-851-0 |
5-«alpha»-Androstan-3-«beta»,16-«alpha»-diol, HFB
|
| 684.50 |
| 25-546-8 |
5-«alpha»-Androstan-7-«beta»,17-«beta»-diol, HFB
|
| 684.50 |
| 64-466-4 |
5-«beta»-Androstan-3-«beta»,17-«alpha»-diol, HFB
|
| 684.50 |
| 64-523-0 |
5-«beta»-Androstan-3-«alpha»,17-«beta»-diol, HFB
|
| 684.50 |
| 20-432-9 |
5-«beta»-Androstan-3-«beta»,17-«beta»-diol, HFB
|
| 684.50 |
| 56-204-3 |
5-«alpha»-Androstan-3-«alpha»,17-«beta»-diol, HFB
|
| 684.50 |
| 26-301-8 |
5-«alpha»-Androstan-3-«beta»,17-«alpha»-diol, HFB
|
| 684.50 |
| 55-759-9 |
2(1H)-Pyrimidinone, 1-[2,3-bis-O-(trimethylsilyl)-«beta»-D-ribofuranosyl]-4-(trimethylsiloxy)-, 5'-[bis(trimethylsilyl) phosphate]
|
32645-59-3 | 685.09 |
| 36-458-4 |
uridine-2'(3')-monophosphate, TMS
|
| 685.09 |
| 120-556-1 |
Silica-1,3,5,7-tetramethyl-2,4,6,8-tetraethylporphyrine complex, bis-OTMS
|
| 685.13 |
| 34-914-9 |
Silica-1,3,5,8-tetramethyl-2,4,6,7-tetraethylporphyrine complex, bis-OTMS
|
| 685.13 |
| 71-271-2 |
orange lead
|
1314-41-6 | 685.60 |
| 52-175-0 |
6-Keto-PGF1A, MO-TMS
|
| 686.27 |
| 51-894-3 |
5-Hydroxytryptophan, methyl, 3-PFP
|
| 686.32 |
| 74-623-8 |
Serine-lysine-tyrosine, N(«alpha»,«epsilon»)-trifluoroacetyl-N-O-permethyl derivative
|
| 686.64 |
| 54-343-1 |
Xylotetraose, permethyl
|
| 686.74 |
| 59-845-9 |
tert-Butyl-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(tert-butyldimethylsilyl)oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]dimethylsilane
|
| 687.06 |
| 45-318-9 |
4-[2-(4-Allyl-2,6-dimethoxy-phenoxy)-1-hydroxy-propyl]-2-methoxy-phenol, TPS
|
| 687.11 |
| 114-105-8 |
Glyceryl-glycoside TMS ether
|
| 687.32 |
| 48-994-6 |
Bis(tetradecanoyloxy)dibutyl tin
|
28660-67-5 | 687.66 |
| 64-299-0 |
Tris(di-n-butyldithiocarbamato)arsenic(III)
|
48233-55-2 | 688.05 |
| 54-636-6 |
TxB2, MO-TMS
|
| 688.25 |
| 120-374-3 |
Isobutyl glucuronide, PFP
|
| 688.29 |
| 116-380-1 |
Butyl glucuronide, PFP
|
| 688.29 |
| 70-352-3 |
(R)-2-Butyl glucuronide, PFP
|
| 688.29 |
| 43-687-2 |
(S)-2-Butyl glucuronide, PFP
|
| 688.29 |
| 64-903-8 |
Ethinylestradiol, HFB
|
| 688.45 |
| 38-867-8 |
Heptadecafluorononanoic acid, hexadecyl ester
|
| 688.50 |
| 27-082-1 |
D-(+)-Glucose, pentakis(trifluoroacetate), methyloxime (syn)
|
| 689.24 |
| 16-051-7 |
D-(+)-Galactose, pentakis(trifluoroacetate), methyloxime (syn)
|
| 689.24 |
| 47-145-9 |
D-(+)-Mannose, pentakis(trifluoroacetate), methyloxime (syn)
|
| 689.24 |
| 70-331-6 |
D-Allose, pentakis(trifluoroacetate), methyloxime (anti)
|
| 689.24 |
| 51-310-0 |
D-Allose, pentakis(trifluoroacetate), methyloxime (syn)
|
| 689.24 |
| 28-139-7 |
D-(+)-Talose, pentakis(trifluoroacetate), methyloxime (syn)
|
| 689.24 |
| 70-330-7 |
D-(+)-Galactose, pentakis(trifluoroacetate), methyloxime (anti)
|
| 689.24 |
| 51-066-2 |
D-(+)-Talose, pentakis(trifluoroacetate), methyloxime (anti)
|
| 689.24 |
| 70-332-5 |
D-(+)-Mannose, pentakis(trifluoroacetate), methyloxime (anti)
|
| 689.24 |
| 70-342-4 |
D-(+)-Glucose, pentakis(trifluoroacetate), methyloxime (anti)
|
| 689.24 |
| 69-535-2 |
5«beta»-Pregnane-3«alpha»,17«alpha»,20«alpha»-triol, (3,20-O)-diTMTBSi, (17-O)-TMSi
|
| 689.29 |
| 51-026-6 |
5«beta»-Pregnane-3«alpha»,17«alpha»,20«alpha»-triol, (3,17-O)-diTMTBSi, (20-O)-TMSi
|
| 689.29 |
| 41-919-6 |
Lead[ii] bis(dibutyldithiophosphate)
|
43159-18-8 | 689.90 |
| 23-239-1 |
Lead(II) pentadecanoate
|
63400-06-6 | 690.00 |
| 81-589-9 |
Praseodymium, tris(2,2,6,6-tetramethyl-3,5-heptanedionato-O,O')-, (OC-6-11)-
|
15492-48-5 | 690.71 |
| 71-023-7 |
Tetratriacontyl heptafluorobutyrate
|
| 690.94 |
| 12-575-0 |
Trimethyl-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-trimethylsilyloxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]silane
|
| 691.01 |
| 118-857-0 |
Ammonium yttrium oxalate, hydrate
|
| 692.07 |
| 13-349-0 |
adenosine-3'-monophosphate, TMS
|
| 692.13 |
| 114-708-9 |
6,7-Dehydro-20-hydroxy-methylprednisolone, MO-tetraTMS (1)
|
| 692.24 |
| 125-205-5 |
6,7-Dehydro-20-hydroxy-methylprednisolone, MO-tetraTMS (3)
|
| 692.24 |
| 121-284-2 |
6,7-Dehydro-20-hydroxy-methylprednisolone, MO-tetraTMS (2)
|
| 692.24 |
| 119-062-1 |
6,7-Dehydro-20-hydroxy-methylprednisolone, MO-tetraTMS (4)
|
| 692.24 |
| 73-594-2 |
Laricitrin (5TMS)
|
| 693.17 |
| 72-023-6 |
2,2,4,4,6,6,8,8-octamethyl-10,10,12,12-tetraphenyl-[1,3,5,7,9,11,2,4,6,8,10,12]cyclohexasiloxane
|
| 693.20 |
| 119-760-6 |
«alpha»-Glucopyranose phosphate, hexakis-TMS
|
| 693.22 |
| 121-580-3 |
«alpha»-D-Glucopyranose, 2,3,4,6-tetrakis-O-(trimethylsilyl)-, bis(trimethylsilyl) phosphate
|
55520-79-1 | 693.22 |
| 70-033-7 |
(24Z)-Trihydroxy-24-coprostenic acid, Me-TMS
|
| 693.23 |
| 13-765-8 |
(24E)-Trihydroxy-24-coprostenic acid, Me-TMS
|
| 693.23 |
| 42-206-6 |
4-Cholenoic acid, 7-«beta»-ol-3-one, TMS
|
| 693.26 |
| 64-241-3 |
4-Cholenoic acid, 7-«alpha»-ol-3-one, TMS
|
| 693.26 |
| 24-117-5 |
7«alpha»,12«alpha»-dihydroxy-3-oxy-4-chol-24-oate, TMS
|
| 693.26 |
| 47-315-0 |
5-Cholenoic acid, 3-«beta»-ol-7-one, TMS
|
| 693.26 |
| 74-872-2 |
Cyclo-tris(diphenoxyphosphonitrile)
|
1184-10-7 | 693.56 |
| 19-583-4 |
Gallium-octaethylporphyrine complex, OTMS
|
| 693.69 |
| 61-013-9 |
Methyl glucosinolate, TMS
|
| 694.24 |
| 114-249-9 |
20-hydroxy-methylprednisolone, MO-tetraTMS (1)
|
| 694.25 |
| 113-788-2 |
20-hydroxy-methylprednisolone, MO-tetraTMS (3)
|
| 694.25 |
| 123-980-7 |
20-hydroxy-methylprednisolone, MO-tetraTMS (2)
|
| 694.25 |
| 121-266-2 |
20-hydroxy-methylprednisolone, MO-tetraTMS (4)
|
| 694.25 |
| 55-628-4 |
2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2,2,2-Trifluoroacetyl)oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 2,2,2-trifluoroacetate
|
| 694.61 |
|
« Previous Results
Next Results »
|